FMEA Stock Chart & Stats
€21.00
-€0.20(-0.94%)
At close: 4:00 PM EDT
€21.00
-€0.20(-0.94%)
Day’s Range― - ―
52-Week Range€17.20 - €23.60
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€11.50B
Enterprise Value€24.81K
Total Cash (Recent Filing)€1.62B
Total Debt (Recent Filing)€11.03B
Price to Earnings (P/E)13.2
Beta0.44
Next Earnings
Aug 04, 2026EPS Estimate
0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding537,129,300
10 Day Avg. Volume8
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.83
Price to Sales (P/S)0.60
P/FCF Ratio6.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.18Price Target Upside-3.91% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)2.01
Revenue Forecast (FY)€19.58B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent, sizeable operating cash flow and materially positive free cash flow provide durable internal funding for capex, R&D, dividends and buybacks. Strong cash conversion reduces reliance on external financing and gives flexibility to absorb reimbursement or volume shocks over the medium term.
Clinical & Product LeadershipA large-scale rollout of the 5008X CAREsystem cements installed-base advantages, locks in consumables demand and improves clinical outcomes. The differentiated platform and broad conversion create recurring consumables revenue and competitive switching costs that support structural revenue and margin durability.
Margin Recovery And Capital AllocationSustained cost savings from FME25+, margin expansion and active capital returns (buybacks/dividend) reflect improved operating discipline and capital allocation. Lower net leverage enhances financial flexibility, enabling continued investment in growth and resilience to industry reimbursement headwinds.
Bears Say
TDAPA Phasing RiskRegulatory reimbursement timing (TDAPA) created sizable one‑period benefit that is expected to reverse in H2. Such phasing injects recurring‑reimbursement uncertainty into annual results, complicates margin sustainability and planning, and can materially depress reported earnings when the benefit lapses.
China Regulatory PressureAdverse procurement/tender dynamics in China are structural policy risks that can compress volumes and pricing for products and services. Given China’s share of Care Enablement revenue, sustained tender pressure can reduce growth and margins in a key geographic market over multiple quarters.
U.S. Clinic Restructuring & Special ItemsAccelerated clinic exits and large one‑off charges highlight execution risk: while intended to improve long‑term efficiency, closures can displace patients, lower utilization and create short‑to‑medium term margin pressure. Realized benefits depend on retaining patients in nearby centers and efficient consolidation.
FMEA FAQ
What was Fresenius Medical Care’s price range in the past 12 months?
Fresenius Medical Care lowest stock price was €17.20 and its highest was €23.60 in the past 12 months.
What is Fresenius Medical Care’s market cap?
Fresenius Medical Care’s market cap is €11.50B.
When is Fresenius Medical Care’s upcoming earnings report date?
Fresenius Medical Care’s upcoming earnings report date is Aug 04, 2026 which is in 4 days.
How were Fresenius Medical Care’s earnings last quarter?
Fresenius Medical Care released its earnings results on May 05, 2026. The company reported €0.463 earnings per share for the quarter, missing the consensus estimate of €0.525 by -€0.062.
Is Fresenius Medical Care overvalued?
According to Wall Street analysts Fresenius Medical Care’s price is currently Overvalued.
Does Fresenius Medical Care pay dividends?
Fresenius Medical Care does not currently pay dividends.
What is Fresenius Medical Care’s EPS estimate?
Fresenius Medical Care’s EPS estimate is 0.53.
How many shares outstanding does Fresenius Medical Care have?
Fresenius Medical Care has 537,129,300 shares outstanding.
What happened to Fresenius Medical Care’s price movement after its last earnings report?
Fresenius Medical Care reported an EPS of €0.463 in its last earnings report, missing expectations of €0.525. Following the earnings report the stock price went down -3.706%.
Which hedge fund is a major shareholder of Fresenius Medical Care?
Currently, no hedge funds are holding shares in DE:FMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€20.18 (-3.91% Downside)
€20.18 (-3.91% Downside)
Blogger Sentiment
Bullish
DE:FMEA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.53%
12-Months-Change
Fundamentals
Return on Equity
3.45%
Trailing 12-Months
Asset Growth
2.54%
Trailing 12-Months
Company Description
Fresenius Medical Care
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
FMEA Company Deck
FMEA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously positive operational and financial start to 2026: solid top‑line organic growth (4%), strong operating income growth (+10%) and margin expansion, meaningful FME25+ savings (EUR 50m), successful accelerated EUR 1bn share buyback, improved cash generation and clear progress on the 5008X rollout and clinical quality initiatives (90% catheter lock adoption, >100k 5008X treatments). Offsetting these positives are near‑term headwinds: front‑loaded restructuring/special costs (EUR 181m), regulatory pressures in China, U.S. volume challenges driven by weather, ACA subsidy expiry and elevated mortality, and a TDAPA phasing effect that is expected to be a material negative in H2 2026. Management confirmed the full‑year outlook and emphasized the temporary/phasing nature of several negatives, supporting a constructive but cautious tone.View all DE:FMEA earnings summariesFMEA Stock 12 Month Forecast
Average Price Target
€20.18
▼(-3.91% Downside)